{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:13:37Z","timestamp":1768716817558,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003970","name":"Isfahan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003970","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.10.013","type":"journal-article","created":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T02:25:11Z","timestamp":1540002311000},"page":"127-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome"],"prefix":"10.1016","volume":"27","author":[{"given":"Masoud","family":"Etemadifar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maedeh","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehri","family":"Salari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Etemadifar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2018.10.013_bib0001","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10384-018-0561-1","article-title":"Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis","volume":"62","author":"Kezuka","year":"2018","journal-title":"Jpn. J. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2018.10.013_bib0002","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult. Scler. J."},{"issue":"6","key":"10.1016\/j.msard.2018.10.013_bib1032","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"14","key":"10.1016\/j.msard.2018.10.013_bib0003","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1177\/1352458517734070","article-title":"A population-based prospective study of optic neuritis","volume":"23","author":"Soelberg","year":"2017","journal-title":"Mult. Scler. J."},{"issue":"10","key":"10.1016\/j.msard.2018.10.013_bib0004","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1590\/0004-282x20170121","article-title":"MOG-IgG associated optic neuritis is not multiple sclerosis","volume":"75","author":"Costa","year":"2017","journal-title":"Arq. Neuropsiquiatr."},{"issue":"1","key":"10.1016\/j.msard.2018.10.013_bib0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.braindev.2014.02.002","article-title":"Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis","volume":"37","author":"Tsuburaya","year":"2015","journal-title":"Brain Dev."},{"issue":"8","key":"10.1016\/j.msard.2018.10.013_bib0006","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2013.118","article-title":"The spectrum of MOG autoantibody-associated demyelinating diseases","volume":"9","author":"Reindl","year":"2013","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2018.10.013_bib0007","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler. J."},{"issue":"1","key":"10.1016\/j.msard.2018.10.013_bib0008","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"issue":"4","key":"10.1016\/j.msard.2018.10.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007766","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis","volume":"5","author":"Nakajima","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.msard.2018.10.013_bib0010","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol.-Neuroimmunol. Neuroinflamm."},{"issue":"12","key":"10.1016\/j.msard.2018.10.013_bib0011","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1212\/WNL.0000000000000830","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"83","author":"Mao","year":"2014","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2018.10.013_bib0012","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1212\/WNL.0b013e31826aac4e","article-title":"Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype","volume":"79","author":"Kitley","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2018.10.013_bib0013","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"issue":"8","key":"10.1016\/j.msard.2018.10.013_bib0014","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1177\/1352458512470310","article-title":"Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica","volume":"19","author":"Rostasy","year":"2013","journal-title":"Mult. Scler. J."},{"issue":"3","key":"10.1016\/j.msard.2018.10.013_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/NRL.0000000000000122","article-title":"Recurrent optic neuritis associated with MOG antibody seropositivity","volume":"22","author":"Chang","year":"2017","journal-title":"Neurologist"},{"issue":"1","key":"10.1016\/j.msard.2018.10.013_bib0017","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12974-015-0256-1","article-title":"Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype","volume":"12","author":"Pr\u00f6bstel","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"3","key":"10.1016\/j.msard.2018.10.013_bib0018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jnnp-2014-308346","article-title":"Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein","volume":"86","author":"Baumann","year":"2015","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"6","key":"10.1016\/j.msard.2018.10.013_bib0019","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2169\/internalmedicine.55.5727","article-title":"An adult case of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated multiphasic acute disseminated encephalomyelitis at 33-year intervals","volume":"55","author":"Numa","year":"2016","journal-title":"Intern. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:54Z","timestamp":1761900234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":19,"alternative-id":["S2211034818303754"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.10.013","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing myelin oligodendrocyte glycoprotein antibody (MOG-Ab) and non MOG-Ab associated optic neuritis: Clinical course and treatment outcome","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}